Katherine L Nathanson

发表

Abstract 1996: Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns

Gyan Bhanot, Shridar Ganesan, Michael Seiler, 2010 .

Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer

Nandita Mitra, Muredach P Reilly, Andrew K Godwin, 2009, Nature Genetics.

Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.

Andrej Sali, Rachel Karchin, Rebecca Sutphen, 2007, Cancer research.

A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia

Rohini Rau-Murthy, Jinghui Zhang, Kenneth Offit, 2013, Nature Genetics.

Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2 negative patients with early onset breast cancer

Angela DeMichele, K. Nathanson, A. DeMichele, 2014, Genetics in Medicine.

Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.

Christiana Kartsonaki, Mads Thomassen, Etienne Rouleau, 2011, Human molecular genetics.

Measurements of Tumor Cell Autophagy Predict Invasiveness, Resistance to Chemotherapy, and Survival in Melanoma

K. Nathanson, R. Amaravadi, J. Lum, 2011, Clinical Cancer Research.

Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.

Mads Thomassen, Nina Ditsch, Dieter Niederacher, 2009, Human molecular genetics.

Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.

Nandita Mitra, Georgia Chenevix-Trench, Susan L Neuhausen, 2009, Cancer research.

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

Wei Lu, Wei Zheng, Mads Thomassen, 2013, Nature Genetics.

Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes

Javier Benítez, J. Benítez, K. Nathanson, 2009, Breast Cancer Research.

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

Dong Liang, Patrick Neven, Harvey Risch, 2016, Journal of the National Cancer Institute.

Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations

Nazneen Rahman, Carel Meijers, Julian Peto, 2002, Nature Genetics.

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

Damien Kee, Xiaowei Xu, Meenhard Herlyn, 2010, Cancer cell.

A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population

Christiana Kartsonaki, Mads Thomassen, Julian Peto, 2010, Nature Genetics.

Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers

Peter Devilee, Alfons Meindl, Lesley McGuffog, 2010, Breast Cancer Research.

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

Mads Thomassen, Nina Ditsch, Muhammad Usman Rashid, 2015, JAMA.

Gene-panel sequencing and the prediction of breast-cancer risk.

Nazneen Rahman, Peter Devilee, Alfons Meindl, 2015, The New England journal of medicine.

Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers

Daniel L Gillen, Susan L Neuhausen, Fergus Couch, 2009, Breast Cancer Research.

Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma.

Antonio L Amelio, Ignaty Leshchiner, Vonn Walter, 2017, Cancer cell.

Molecular and Cellular Pathobiology Integrative Genomic Analyses of Sporadic Clear Cell Renal Cell Carcinoma De fi ne Disease Subtypes and Potential New Therapeutic Targets

John D Gordan, Vijay R Dondeti, K. Nathanson, 2011 .

Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.

Nazneen Rahman, Carel Meijers, Sheila Seal, 2003, American journal of human genetics.

Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.

T. Rebbeck, B. Weber, K. Nathanson, 2002, Journal of the National Cancer Institute.

HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.

Brian Keith, Keith T Flaherty, John D Gordan, 2008, Cancer cell.

The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families.

T. Rebbeck, K. Nathanson, S. Domchek, 2008, Cancer research.

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2

Mads Thomassen, Stephen Fox, Dieter Niederacher, 2011, Breast Cancer Research.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Yiling Lu, Lauren E Haydu, Gordon B Mills, 2017, Cell reports.

Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers.

Jing Zhang, Dezheng Huo, Olufunmilayo I Olopade, 2013, Carcinogenesis.

Common breast cancer risk variants in the post-COGS era: a comprehensive review

Katherine L Nathanson, Kara N Maxwell, 2013, Breast Cancer Research.

Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.

Stefania Tommasi, Laura Cortesi, Mads Thomassen, 2019, Cancer research.

Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Dieter Niederacher, Ute Hamann, Alfons Meindl, 2008, American journal of human genetics.